Compare Abbott Laboratories (ABT) vs Bandwidth Inc (BAND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Bandwidth Inc — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Bandwidth Inc trades at $71.14 (market cap $1.94B). The key difference: Abbott Laboratories is far larger — about 86.1× Bandwidth Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| ABT | BAND | |
|---|---|---|
Market Cap | $166.94B | $1.94B |
Sector | Health | Technology |
52-Week High | $136.62 | $73.19 |
52-Week Low | $82.57 | $12.82 |
Enterprise Value | $193.69B | $2.32B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Bandwidth (BAND) trades at $60.67, down 1.51% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $0.38, beating expectations, but maintains negative net income margins. Recent news highlights the launch of the AI-driven Bandwidth Build platform and a $275 million convertible notes offering, fueling growth optimism in cloud communications.
The outlook is mixed: strong analyst buy consensus (75%) and AI expansion offer upside, but profitability concerns and high valuation multiples pose risks. Revenue growth is projected to improve, yet negative ROE and net income require monitoring. The stock's momentum depends on execution of AI initiatives and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →
